Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by G1 Therapeutics
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
December 05, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
November 29, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
November 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
October 27, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
October 18, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
October 16, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
August 02, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
July 31, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
June 04, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
May 16, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
May 10, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
May 03, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
February 13, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
January 09, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
December 07, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Closing of Offering of Common Stock
November 22, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Pricing of Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Proposed Public Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
November 02, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
November 02, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
October 10, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.